More companies in talks for Remdesivir licence

This week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received emergency use authorisation from the US Food and Drug Administration after trial results showed that it halved the recovery time to five days for moderately affected patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news